CJC-1295 / Ipamorelin blend (no DAC)
5 mg / 5 mg blend
This blend combines CJC-1295, a GHRH analogue, with ipamorelin, a ghrelin-receptor secretagogue, on the theory that pairing the two produces more growth-hormone release than either alone.
Regulatory status: Not FDA-approved. Neither peptide is approved for the marketed uses, and no trial of the combination has been published or registered.
Default vial
10 mg
Default mix
2 mL
Reported range
100–300 mcg of each per dose
Draw (U-100)
4 u
Pre-mixed 5 mg CJC-1295 (no DAC) + 5 mg Ipamorelin in one vial, so each draw delivers equal mcg of both. Dose fasted AM and pre-bed.
What it is
- A compounded combination product; vendor ratios and doses vary and are verifiable only via Certificate of Analysis.
- Unlike the repair blends, each component has some individual human pharmacology data — most substantially for CJC-1295 with DAC.
- Marketed off-label for anti-ageing, fat loss and muscle gain, none of which is an approved indication for either peptide.
- Blend listings often do not specify whether the CJC-1295 component includes the DAC modification, which changes its duration substantially.
How it is described to act
- 1
Injected subcutaneously in practice; the combination has no studied regimen.
- 2
CJC-1295 is proposed to give sustained GHRH-receptor activity, raising GH and IGF-1, based on human pharmacokinetic work.
- 3
Ipamorelin is proposed to stimulate GH release selectively via the ghrelin receptor, reportedly with less effect on cortisol and prolactin than older secretagogues — a finding from early-phase and animal work.
- 4
Proponents argue the two together produce more sustained pulsatile GH release, but that combined effect has not been tested in a published trial.
What the research has looked at
Component-level human data
- Teichman et al. (J Clin Endocrinol Metab, 2006) reported prolonged GH and IGF-1 elevation after CJC-1295 with DAC in healthy adults.
- Ipamorelin's human record is essentially one 1999 pharmacokinetic study in volunteers; the rest is preclinical.
No blend-level evidence
- No PubMed or ClinicalTrials.gov entry testing CJC-1295 and ipamorelin together as a product was located.
Strength of evidence: Preclinical evidence only
Each component has some human pharmacology data, but the combination itself has none, and the marketed body-composition claims rest on general GH physiology rather than trials of this product.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- GH secretagogues can affect blood glucose and fluid balance; long-term safety of chronic off-label use is not established.
- Combining two compounds active on the same axis increases uncertainty about cumulative endocrine effects, which has not been studied.
- Compounded sourcing means purity and dosing are unverified without a Certificate of Analysis.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
CJC-1295 / Ipamorelin blend (no DAC) questions people ask
How do you reconstitute CJC-1295 / Ipamorelin blend (no DAC)?
A common starting point for a 10 mg vial of CJC-1295 / Ipamorelin blend (no DAC) is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of CJC-1295 / Ipamorelin blend (no DAC) is one dose?
At 5 mg per mL, that works out to about 4 units on a U-100 insulin syringe for a 200 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for CJC-1295 / Ipamorelin blend (no DAC)?
Published and community sources describe 100–300 mcg of each per dose, subcutaneous, every day, typically run 8 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should CJC-1295 / Ipamorelin blend (no DAC) be stored?
Lyophilized CJC-1295 / Ipamorelin blend (no DAC) vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.